ProjectAuswertung und Veröffentlichung der STudie "Pro-Symbioflor bei Reizdarmsyndrom"
Basic data
Title:
Auswertung und Veröffentlichung der STudie "Pro-Symbioflor bei Reizdarmsyndrom"
Duration:
01/12/2018 to 30/06/2020
Abstract / short description:
The drug company Symbiopharm had conducted a randomized, placebo-controlled trial of a probiotic product (Pro-Symbioflor) in > 350 patients with irritable bowel syndrome (IBS) betqween 2014 and 2018. The results of this study were submitted to BfArM for marketing approval (Nachzulassung). The data of this study are to evaluated and publish under three points of view: a) global effecacy, b) analysis of drop-outs; c) analysis of placebo responders.
Involved staff
Managers
Faculty of Medicine
University of Tübingen
University of Tübingen
Local organizational units
Department VI, Psychosomatics
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Herborn, Hessen, Germany